Healthcare

Microbix Commercializes Custom Biologic Materials After Initial Sales to Two DxMs

Microbix Biosystems says it has commercialized custom biological materials for diagnostic assay manufacturers, with initial sales to two customers.

Published:
Reading Time
3 min

Microbix Biosystems Inc. (TSX:MBX; OTCQX:MBXBF) has commercialized custom biological materials intended for use in laboratory assays and point-of-care test cartridges made by in-vitro diagnostics manufacturers. The company said initial sales have been made to two diagnostics manufacturers, with each incorporating a Microbix material into a new assay or assays.

#Materials to be used as sample processing controls

The materials are supplied to diagnostics manufacturers for additional manufacturing before being built into finished tests as sample processing controls, or SPCs. These controls are non-target biological materials processed alongside patient samples.

When a test does not detect its target but the SPC does not work, the result is classified as invalid rather than negative. Once incorporated into an assay, the Microbix materials are intended to help verify that key steps, including nucleic-acid extraction, amplification and detection, have operated correctly.

#Support for DNA and RNA assays

Microbix said the new materials can support both DNA-based and RNA-based molecular assays. For RNA applications, the materials also cover the reverse-transcription step.

The company said this product class complements its QAPs™ external quality assessment products and QUANTDx™ reference materials. Microbix said all three classes can use customised nucleic-acid sequences designed around the targeting requirements of diagnostics manufacturers.

#Sales outlook and management comments

Microbix said it expects to generate recurring sales to the two initial diagnostics-manufacturer customers and expects to secure additional customers for the materials. The company said sales of the category are targeted to become material as customer assays are commercialized and additional customer programmes and customers are secured.

Phil Casselli, Microbix’s SVP of Sales & Business Development, said SPC-oriented materials differ from external quality assessment samples because the diagnostics manufacturer incorporates them into each test unit. External assessment samples are used periodically by clinical laboratories or may be included one per box with test cartridges, according to Casselli.

Pavel Zhelev, Microbix’s Director of Product Management, said test designs can fail for multiple reasons. He said an SPC that verifies whether each test has run correctly is needed for regulatory approvals and reimbursement, best-practice use and patient safety.

#Microbix business background

Microbix is a Canadian life sciences company whose biological products support diagnostic testing, laboratory quality assurance and disease management. The company said it has over 100 employees and reported fiscal 2025 revenues of C$18.6 million.

Microbix said its products are available in more than 30 countries through international distribution partners. Its proprietary antigens are used by approximately 100 diagnostics manufacturers, alongside its QAPs™ quality assessment products and QUANTDx™ reference materials. The company is headquartered in Mississauga, Ontario, and trades on the TSX and OTCQX.

#Forward-looking information

Microbix said statements about recurring sales, additional customers and the future materiality of the product category are forward-looking information based on management’s estimates, beliefs, intentions and expectations. The company cautioned that these statements are not guarantees of future performance and that actual events, conditions and results may differ materially.

Risks identified by Microbix include regulatory compliance and approvals, sales in foreign jurisdictions, production controls, currency exchange rates, working capital and the ability to raise capital on acceptable terms or at all.

#Key Takeaways

  • Microbix has commercialized custom biologic materials for incorporation into diagnostic assays and point-of-care test cartridges.
  • Initial sales have been made to two diagnostics manufacturers, each using a Microbix material in a new assay or assays.
  • The materials are designed for use as sample processing controls in DNA- and RNA-based molecular tests.
  • Microbix expects recurring sales and additional customers, while stating that future sales materiality depends on assay commercialization and further customer programmes.

Original source: Read original article

Frequently Asked Questions